Sector News

Cardinal Health buys Medtronic units for $6B

April 19, 2017
Life sciences

Cardinal Health said Tuesday it had agreed to acquire Medtronic’s medical supplies units for $6.1 billion but shares of the medical device giant plunged on a forecast for fiscal 2017 earnings that was at the low end of its earlier guidance.

Medtronic’s patient care, deep vein thrombosis and nutritional insufficiency units span 23 product categories across multiple markets, including brands such as Curity, Kendall, Dover, Argyle and Kangaroo that are used in nearly every U.S. hospital. They generated about $2.4 billion in revenue in the last four reported quarters.

The deal will expand Cardinal’s growing medical products business.

“Given the current trends in healthcare, including aging demographics and a focus on post-acute care, this industry-leading portfolio will help us further expand our scope in the operating room, in long-term care facilities and in home healthcare, reaching customers across the entire continuum of care,” Cardinal CEO George S. Barrett said in a news release.

Analysts also cheered the move. “We believe [the acquisition] fits well into Cardinal Health’s strategy in medical, and continues to diversify the business away from pharma distribution,” Cowen & Co.’s Charles Rhyee wrote.

Cardinal expects the acquisition to be accretive to non-GAAP diluted earnings per share by more than $0.55 per share in fiscal 2019, and increasingly accretive thereafter.

But the company also announced Tuesday that it expects fiscal 2017 earnings per share at the low end of earlier guidance of $5.35 to $5.50 per share, compared with the FactSet consensus of $5.42. It cited generic price deflation in its pharmaceutical business.

In trading Tuesday, Cardinal shares dropped 11.5% to $72.39. The stock had jumped 8.0% over the past three months, compared to a 3.4% rise in the S&P 500.

“The weaker guidance, which includes the positive accretion from Medtronic’s supply business, is concerning for the distributor sector,” Mizuho Securities USA analyst Ann Hynes told Reuters.

Cardinal said it will fund the Medtronic deal with $4.5 billion in new debt plus existing cash. That prompted Fitch Ratings to express concerns over Cardinal’s debt burden and lower its outlook on the company.

By Matthew Heller

Source: CFO

comments closed

Related News

September 22, 2023

Novo Holdings acquires biopharma company Paratek for $462m

Life sciences

Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.

September 22, 2023

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Life sciences

Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).

September 22, 2023

Lonza-CEO Ruffieux to leave Swiss CDMO

Life sciences

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.

How can we help you?

We're easy to reach